ACEBUTOLOL SUMMARY
ACEBUTOLOL
HYDROCHLORIDE
CAPSULES, USP
mg and 400 mg
Acebutolol hydrochloride is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias. It is marketed in capsule form for oral administration.
Acebutolol is indicated for the following:
Hypertension
Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Ventricular Arrhythmias
Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats.
|
NEWS HIGHLIGHTS
Published Studies Related to Acebutolol
Effects of grapefruit juice on the pharmacokinetics of acebutolol. [2005.12]
AIMS: We aimed to investigate effects of grapefruit juice on acebutolol pharmacokinetics... CONCLUSION: Grapefruit juice caused a small decrease in the plasma concentrations of acebutolol and diacetolol by interfering with gastrointestinal absorption. The interaction between the grapefruit juice and acebutolol is unlikely to be of clinical significance in most of the patients.
Comparison of the effect of perindopril and acebutolol on cerebral hemodynamics in hypertensive patients. [2001.01]
PURPOSE: The aim of the study was to compare effect of perindopril (4 mg once a day) versus acebutolol (400 mg once a day) on cerebral hemodynamics in hypertensive patients... CONCLUSIONS: Among patients with mild-to-moderate hypertension both acebutolol and perindopril beneficially decreased cerebrovascular resistance and increased the CBF index in comparison with placebo. The increase of CBF index was greater after perindopril than acebutolol, which suggests a more significant improvement in cerebral perfusion by perindopril. The non-invasive transcranial Doppler ultrasonography method of CBF velocity measurement may contribute to choosing optimal antihypertensive therapies and to monitor their effect.
[The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment] [2001]
Hypertension is one of the most important risk factors for ischaemic heart disease and stroke. The aim of our study was to assess the antihypertensive effect of angiotensine converting enzyme inhibitor (perindopril) versus beta blocker (acebutolol) in hypertensive patients... After 3 weeks of the treatment we observed BP systolic and diastolic normalization, but more patients had systolic BP normalization after perindopril treatment.
Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. [1999.07.01]
In the present study, we assessed the antihypertensive efficacy of acebutolol 200 mg versus carvedilol 25 mg once daily, given as monotherapy for 3 months to 40 black patients (20 patients in each group, mean age 53+/-10 years, 24 women) with mean blood pressure (BP) during the day >90 and <110 mm Hg.
Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery. [1997.04.15]
In this study, a beta-adrenergic blocker in combination with digoxin provided marginal protection against atrial fibrillation/flutter after coronary artery surgery. The economic comparison of patients who did and did not develop atrial fibrillation/flutter indicates that prevention of these arrhythmias can have a significant impact on length of hospital stay and cost of this common surgical procedure..
Clinical Trials Related to Acebutolol
Treatment of Mild Hypertension Study (TOMHS) [Completed]
To compare the effects of nonpharmacologic therapy alone with those of one of five active
drug regimens combined with non-pharmacologic therapy, for long- term management of patients
with mild hypertension.
Michigan Driver Education Study [Completed]
Teens are at high risk for traffic violations and car crashes because of their young age,
lack of driving experience, and exposure to high-risk driving conditions. The Checkpoints
Program has used increased parental restrictions on teen driving through at least the first 4
months after their children obtain a driver's permit.
The purpose of this study is to evaluate the efficacy of the Checkpoints
Program.
Approximately 400 teens in Michigan will participate in one of two study groups. One group
will take standard driver education classes; the other group will take driver education
classes that incorporate the Checkpoints Program. Teens and their parents will complete a
written survey after completing the classes and a telephone survey after teens obtain a
driver's permit. Teens will complete additional telephone surveys 1, 3, 6, and 12 months
after obtaining a driver's permit. Researchers will use this information to study how
parents manage teen driving practices, teen driving experiences (amount and conditions of),
and high-risk teen driving behaviors.
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial [Recruiting]
CABANA is designed to test the hypothesis that the treatment strategy of percutaneous left
atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is
superior to current state-of-the-art therapy with either rate control or anti-arrhythmic
drugs for reducing total mortality (primary endpoint) and decreasing the composite endpoint
of total mortality, disabling stroke, serious bleeding and cardiac arrest (secondary
endpoint) in patients with untreated or incompletely treated AF warranting therapy.
Ablation Versus Anti-Arrhythmic (AA) Drug Therapy for AF - Pivotal Trial [Not yet recruiting]
The CABANA Trial has the overall goal of establishing the appropriate roles for medical and
ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the
hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of
eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy
with either rate control or rhythm control drugs for reducing total mortality in patients
with untreated or incompletely treated AF.
|
